JP2024527974A5 - - Google Patents

Info

Publication number
JP2024527974A5
JP2024527974A5 JP2024504984A JP2024504984A JP2024527974A5 JP 2024527974 A5 JP2024527974 A5 JP 2024527974A5 JP 2024504984 A JP2024504984 A JP 2024504984A JP 2024504984 A JP2024504984 A JP 2024504984A JP 2024527974 A5 JP2024527974 A5 JP 2024527974A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/110539 external-priority patent/WO2023011631A1/zh
Publication of JP2024527974A publication Critical patent/JP2024527974A/ja
Publication of JP2024527974A5 publication Critical patent/JP2024527974A5/ja
Pending legal-status Critical Current

Links

JP2024504984A 2021-08-05 2022-08-05 小細胞肺がんを治療する薬物の組み合わせ Pending JP2024527974A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110897167.2 2021-08-05
CN202110897167 2021-08-05
PCT/CN2022/110539 WO2023011631A1 (zh) 2021-08-05 2022-08-05 治疗小细胞肺癌的药物组合

Publications (2)

Publication Number Publication Date
JP2024527974A JP2024527974A (ja) 2024-07-26
JP2024527974A5 true JP2024527974A5 (cg-RX-API-DMAC7.html) 2025-08-13

Family

ID=85154833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504984A Pending JP2024527974A (ja) 2021-08-05 2022-08-05 小細胞肺がんを治療する薬物の組み合わせ

Country Status (8)

Country Link
US (1) US20240343807A1 (cg-RX-API-DMAC7.html)
EP (1) EP4382123A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527974A (cg-RX-API-DMAC7.html)
KR (1) KR20240046526A (cg-RX-API-DMAC7.html)
CN (1) CN116209443A (cg-RX-API-DMAC7.html)
AU (1) AU2022321783A1 (cg-RX-API-DMAC7.html)
CA (1) CA3227992A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023011631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118267468A (zh) * 2019-01-25 2024-07-02 正大天晴药业集团股份有限公司 治疗肿瘤的联用药物组合物
WO2024155790A2 (en) * 2023-01-18 2024-07-25 Onkosxcel Therapeutics, Llc Novel approach for treatment of cancer using immunomodulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201901057UA (en) * 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
CN116077647B (zh) * 2018-07-18 2025-06-27 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
SG11202102682SA (en) * 2018-09-18 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Quinoline derivative used for treating small cell lung cancer
CN111617243B (zh) * 2019-02-28 2023-12-19 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
BR112021017678A2 (pt) * 2019-03-07 2021-11-16 Advenchen Pharmaceuticals Llc Uso de catequentinibe (anlotinibe) combinando com quimioterapia padrão ou imunoterapia em ordem sequencial para o tratamento de câncer
CN113613674B (zh) * 2019-03-15 2024-11-05 正大天晴药业集团股份有限公司 治疗小细胞肺癌的联用药物组合物
JP7761490B2 (ja) * 2019-05-20 2025-10-30 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 小細胞肺がんの併用療法用キノリン誘導体
WO2020249018A1 (zh) * 2019-06-10 2020-12-17 正大天晴药业集团南京顺欣制药有限公司 治疗驱动基因阳性肺癌的联用药物组合物
WO2022002153A1 (zh) * 2020-06-30 2022-01-06 正大天晴药业集团股份有限公司 用于治疗肿瘤的药物

Similar Documents

Publication Publication Date Title
Levy et al. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
JP2013520442A5 (cg-RX-API-DMAC7.html)
RU2013126630A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2013542241A5 (cg-RX-API-DMAC7.html)
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2012509889A5 (cg-RX-API-DMAC7.html)
JP2008503476A5 (cg-RX-API-DMAC7.html)
RU2017133273A (ru) Ингибиторы pd-1 / pd-l1 для лечения рака
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
RU2011125518A (ru) Антиангиогенная терапия, применяемая для лечения рака молочной железы
JP2011522773A5 (cg-RX-API-DMAC7.html)
JP2021510725A5 (cg-RX-API-DMAC7.html)
HRP20160045T1 (hr) Metoda lijeäśenja raka pomoä†u antagonista dll4 i kemoterapijskog sredstva
JP2011520921A5 (cg-RX-API-DMAC7.html)
RU2007101378A (ru) Терапия злокачественной опухоли, резистентной к препаратам на основе платины
EP2435041A1 (en) Therapeutic combination comprising a plk1 inhibitor and an antineoplastic agent
EA018447B1 (ru) Применение комбинации 7-(2,5-дигидро-4-имидазо[1,2-а]пиридин-3-ил-2,5-диоксо-1н-пиррол-3-ил)-9-фтор-1,2,3,4-тетрагидро-2-(1-пиперидинилкарбонил)пирроло[3,2,1-jk][1,4]бензодиазепина с химиотерапевтическим агентом для лечения злокачественных опухолей
JP2022512851A5 (cg-RX-API-DMAC7.html)
Sprangers et al. 16 Conventional Chemotherapy
JPWO2022270524A5 (cg-RX-API-DMAC7.html)
JP2024533067A5 (cg-RX-API-DMAC7.html)
JP2007277240A5 (cg-RX-API-DMAC7.html)
Tanaka et al. Combination effects of irradiation and irinotecan on cervical squamous cell carcinoma cells in vitro
JP2023531090A5 (cg-RX-API-DMAC7.html)